Immunome
A biopharmaceutical company
Monday, November 19, 2012
Embassy Suites, Chesterbrook, Pennsylvania (directions)
|
About
|
Immunome is a biopharmaceutical company that has worldwide, exclusive license to the patented Acceleroma platform for cloning Native Human Monoclonal Antibodies (N-huMAbs), antibodies that result from the natural protective functions of the human immune system. N-huMAbs cannot be accessed using conventional, non-human model systems. Immunome’s H-huMAbs have undergone the refinement and optimization that occurs in the lymph node and spleen of a human body fighting for its survival. Immunome’s N-huMAbs capture the evolutionary wisdom that has secured survival of the human species.
The most exciting new approach in the treatment of cancer is with antibody drug conjugates (ADCs). ADCs are a new type of targeted therapy consisting of an antibody linked to a cytotoxic, payload drug. The antibody causes the ADC to bind to the target to cancer cells. The ADC is then internalized by the cell and the drug is released to do its damage. Because of the targeting, the side effect profile of ADCs are significantly lower which results in a wider therapeutic window. The traditional approach to creating a cancer antibody drug starts with a known cancer antigen. The problem is that the pharmaceutical pipeline is stuffed with many drugs all going after the same few targets. New targets are needed to create ADCs with expanded activity against diverse tumor types, less resistance, fewer off-target effects, and better survival outcomes.
At Immunome, we don’t need to know upfront what the tumor antigen will be in order to make antibodies with potential therapeutic benefits. With the Immunome Closed Loop Discovery Model, we let the human immune system decide what antigens it would recognize on a tumor cell. The Immunome unique value proposition is a discovery platform that identifies new cancer specific antigens suitable for targeting with an ADC. Simultaneously, the platform identifies antibodies that are leads suitable for clinical development as ADC therapeutics and diagnostics.
3 Major Issues
|
- Immunome’s advantage with its closed-loop antigen/mAb discovery approach will pursue new targets for cancer. Could a new target in cancer therapy be considered a negative since it will not have been “validated”?
- What type of preclinical data would “validate” a newly discovered target for cancer therapy?
- How best to co-develop a theranostic (paired diagnostic and therapeutic)?
Program:
|
6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)
8:00 - Tim Pelura PhD, Chairman, President and CEO of Immunome, will deliver the Company's "Elevator" Pitch to the Group
8:20 - A Panel will address 3 Major Issues for the Company
9:00 - Open discussion: members and guests
<Top of the page>
|
 |
 Slides
None available at this time
 Audio
None available at this time
 Video
None available at this time
 Webcast
Immunome Webcast - 11/19/12
|
|
|
